Investment Summary: Why all the excitement about AML?
• Acute Myeloid Leukemia (AML) is an area of substantial unmet medical need. » One of the worst survival rates of all cancers » Standard of care unchanged in 40 years
• A disease of intense interest for clinicians, pharma companies and investors
• Celator Pharmaceuticals (NASDAQ: CPXX) showed what can happen when enhancing the standard of care in AML » Market cap recently surged from small cap to $780M » Dr Jeff Lancet was the Principal Investigator on CPXX’s ground-breaking trial
• PTX had successful Phase 1 trial in AML (conducted at Moffitt and MD Anderson)
• Dr Lancet is also the Principal Investigator on PTX’s imminent Phase 1b/2 AML trial
• AML trial about to commence with Phase 1b results next year
